James E. Fickenscher
Net Worth
Last updated:
What is James E. Fickenscher net worth?
The estimated net worth of Mr. James E. Fickenscher is at least $5,871,172 as of 13 Sep 2023. He has earned $29,172 from insider trading and has received compensation worth at least $5,842,000 in Zynerba Pharmaceuticals, Inc. and Zynerba Pharmaceuticals, Inc..
What is the salary of James E. Fickenscher?
Mr. James E. Fickenscher salary is $596,620 per year as Chief Financial Officer, Vice President of Corporation Devel. & Treasurer in Zynerba Pharmaceuticals, Inc.. He also receives $582,820 as Chief Financial Officer, Vice President of Corporation Devel. & Treasurer in Zynerba Pharmaceuticals, Inc..
How old is James E. Fickenscher?
Mr. James E. Fickenscher is 61 years old, born in 1964.
What stocks does James E. Fickenscher currently own?
As insider, Mr. James E. Fickenscher owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Zynerba Pharmaceuticals, Inc. (ZYNE) | Chief Financial Officer, Vice President of Corporation Devel. & Treasurer | 378,087 | $0 | $0 |
What does Zynerba Pharmaceuticals, Inc. do?
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
James E. Fickenscher insider trading
Zynerba Pharmaceuticals, Inc.
Mr. James E. Fickenscher has made 3 insider trades between 2016-2023, according to the Form 4 filled with the SEC. Most recently he sold 8,998 units of ZYNE stock worth $11,931 on 13 Sep 2023.
The largest trade he's ever made was exercising 17,769 units of ZYNE stock on 23 Jan 2023. As of 13 Sep 2023 he still owns at least 378,087 units of ZYNE stock.
Zynerba Pharmaceuticals key executives
Zynerba Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Mr. Armando Anido MBA (67) Chairman & Chief Executive Officer
- Mr. James E. Fickenscher (61) Chief Financial Officer, Vice President of Corporation Devel. & Treasurer
- Ms. Terri B. Sebree (67) Pres